New approach helps design better antibiotics to fight drug-resistant infections

https://www.news-medical.net/news/20260529/New-approach-helps-design-better-antibiotics-to-fight-drug-resistant-infections.aspx A new way of designing antibiotics could support the discovery of new treatments for drug-resistant infections. It could also help revive antibiotics that have lost effectiveness because bacteria have evolved over time to survive the drugs meant to kill them.

Novel therapeutic agent proposed to combat drug resistant tuberculosis

https://www.news-medical.net/news/20260529/Novel-therapeutic-agent-proposed-to-combat-drug-resistant-tuberculosis.aspx A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques. The proposed drug is anticipated to bind strongly to the drug-metabolizing enzyme cytochrome P450 (CYP), thereby inhibiting excessive CYP-mediated metabolism and preventing the degradation of co-administered drugs. Additionally, because this agent targets enzymes released by the tuberculosis bacterium rather than the bacterium itself, the likelihood of bacterial mutation and resistance development is reduced, suggesting sustained therapeutic efficacy over an extended period.

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

https://www.news-medical.net/news/20260529/Targeted-therapy-sunvozertinib-outperforms-standard-chemotherapy-in-advanced-lung-cancer-trial.aspx The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.

Consumer wearables become the new gatekeepers of clinical health care

https://www.news-medical.net/news/20260529/Consumer-wearables-become-the-new-gatekeepers-of-clinical-health-care.aspx JMIR Publications today released a News and Perspectives expert analysis on consumer wearable platforms' forays into the clinical health care space. Authored by MedTech expert Blythe Karow, MBA, "Meet the New Health Care Gatekeeper: Your Wearable" lays out the implications of wearable tech companies owning the first conversation about a patient's health, as well as the potential impacts on patient trust, policy, and regulation.

Teclistamab delivers deeper responses in relapsed myeloma patients

https://www.news-medical.net/news/20260529/Teclistamab-delivers-deeper-responses-in-relapsed-myeloma-patients.aspx Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Thyroid function linked to chronotype or daytime sleepiness in women with Hashimoto's thyroiditis

https://www.news-medical.net/news/20260529/Thyroid-function-linked-to-chronotype-or-daytime-sleepiness-in-women-with-Hashimotos-thyroiditis.aspx Hashimoto's thyroiditis (HT), an autoimmune disease with a prevalence 2–7 times higher in women than in men, is associated with daytime sleepiness. The present study aimed to test the hypothesis that thyroid function is associated with chronotype and daytime sleepiness in women with HT.

Gene test helps many breast cancer patients avoid chemotherapy

https://www.news-medical.net/news/20260529/Gene-test-helps-many-breast-cancer-patients-avoid-chemotherapy.aspx Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found. The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) was designed to reduce the use of unnecessary chemotherapy for people with newly diagnosed breast cancer. It followed more than 4,400 patients across the UK, Norway, Sweden, Australia, New Zealand and Thailand.